C40B30/02

Compounds that inhibit human DNA ligases and methods of treating cancer

Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

Method of Identification of Combinatorial Enzymatic Reaction Targets in Glioblastoma Specific Metabolic Network
20180371643 · 2018-12-27 ·

The present invention relates to an in-silico method for identification of enzymatic reaction targets and combinations thereof useful in cancer therapy. Further, the present invention relates to combinatorial targeting of essential metabolites and reactions associated with glioblastoma survival. The present invention provides a way to prevent or treat glioblastoma by regulating/inhibiting a combination of glycine transporter along with one or more enzymes catalyzing the internal glycine serine metabolism.

AUTOMATED METHODS FOR SCALABLE, PARALLELIZED ENZYMATIC BIOPOLYMER SYNTHESIS AND MODIFICATION USING MICROFLUIDIC DEVICES
20180362969 · 2018-12-20 ·

Methods for the automated template-free synthesis of user-defined sequence controlled biopolymers using microfluidic devices are described. The methods facilitate simultaneous synthesis of up to thousands of uniquely addressed biopolymers from the controlled movement and combination of regents as fluid droplets using microfluidic and EWOD-based systems. In some forms, biopolymers including nucleic acids, peptides, carbohydrates, and lipids are synthesized from step-wise assembly of building blocks based on a user-defined sequence of droplet movements. In some forms, the methods synthesize uniquely addressed nucleic acids of up to 1,000 nucleotides in length. Methods for adding, removing and changing barcodes on biopolymers are also provided. Biopolymers synthesized according to the methods, and libraries and databases thereof are also described. Modified biopolymers, including chemically modified nucleotides and biopolymers conjugated to other molecules are described.

METHOD FOR ENCODING AND DECODING LARGE SCALE MOLECULAR VIRTUAL LIBRARIES INTO A BARCODE

Method for encoding and decoding large scale molecular virtual libraries into a barcode Ligand-based drug discovery is often characterized with extraction of scaffolds, linkers and 5 building blocks from large small molecule datasets. Variable sites on scaffolds with attachment sites on building blocks participate in a combinatorial virtual reaction to generate a set of new virtual molecules. This process is time consuming and demands more storage space and is tedious to exchange data digitally. There is practically no quick way to sample molecules without enumerating the virtual library. Therefore, the present invention discloses a method of 10 encoding a virtual library of large scale molecular data into a single barcode. The present invention further discloses a method of decoding the barcode containing large scale data molecules.

SELECTIVE PEPTIDE ANTAGONISTS
20180349550 · 2018-12-06 ·

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

Throughput optimizing reagent distribution

Methods and systems for performing tests in an in vitro diagnostic environment provide for a substantially optimized distribution of testing reagents amongst a plurality of analyzers. The system and method can include steps of identifying a plurality of expected tests to be performed by a plurality of analyzer modules, determining information about the capabilities of the plurality of analyzer modules, and receiving, at the processor, data reflecting which of the plurality of tests are incompatible. Further steps can include calculating a substantially optimal distribution of the plurality of expected tests amongst the plurality of analyzer modules, allocating reagents to each of the plurality of analyzer modules by facilitating distribution of a plurality of reagents to selected analyzer modules in response to the step of calculating, and automatically scheduling a plurality of samples to undergo tests at the plurality of analyzer modules.

Method for mass humanization of non-human antibodies
10125198 · 2018-11-13 · ·

The present invention relates to a method for producing a population of nucleic acids encoding at least one protein comprising at least one immunoglobulin variable domain having a non-human-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.

Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Various scaffolds of small molecules capable of binding to the active site of sortilin are identified by in silico methods. These scaffolds include norbornene anhydride amino acid adducts and 2-substituted 3-oxo-1,2,3,4-tetrahydro-2-quinoxalines. These sortilin ligands increase the uptake of glucose in 3T3L1 cells and can be employed in compositions to increase uptake of glucose for the treatment of diabetic patents.

Systems and Methods for In Silico Drug Discover
20180312999 · 2018-11-01 · ·

Provided herein are methods of computer-assisted identification of a compound that binds to a target protein.

Pharmaceutical platform technology for the development of natural products
10114931 · 2018-10-30 · ·

The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components.